Onyx narrows 4th-qtr 2007 loss to $11.7M

3 March 2008

The USA's Onyx Pharmaceuticals narrowed its loss in the fourth quarter of 2007, despite missing analysts' expectations. The firm's deficit totaled $11.7 million, or $0.21 per share, from $20.7 million, or $0.47 per share, in the same period in the prior year, as net sales of its cancer drug Nexavar (sorafenib) - marketed with Bayer - reached $124.9 million, a 96% increase over fourth-quarter 2006 and a 19% jump in turnover on third-quarter 2007. A Thomson Financial survey found that analysts were expecting a loss of $0.07 per share on sales of $22.0 million.

Hollings Renton, chief executive of Onyx, commented on his high hopes for the drug, saying: "the approvals of Nexavar in liver cancer and advanced kidney cancer reinforce our commitment to invest in Nexavar, both commercially and clinically, to maximize the full value of this proven anticancer agent."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight